Arch Biopartners Inc
XTSX:ARCH

Watchlist Manager
Arch Biopartners Inc Logo
Arch Biopartners Inc
XTSX:ARCH
Watchlist
Price: 1.95 CAD 1.04% Market Closed
Market Cap: 126.1m CAD
Have any thoughts about
Arch Biopartners Inc?
Write Note

Arch Biopartners Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Arch Biopartners Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Arch Biopartners Inc
XTSX:ARCH
Total Current Liabilities
CA$7.6m
CAGR 3-Years
23%
CAGR 5-Years
92%
CAGR 10-Years
32%
Abcellera Biologics Inc
NASDAQ:ABCL
Total Current Liabilities
$119m
CAGR 3-Years
5%
CAGR 5-Years
79%
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Total Current Liabilities
CA$1.5m
CAGR 3-Years
-18%
CAGR 5-Years
-5%
CAGR 10-Years
15%
Innovotech Inc
XTSX:IOT
Total Current Liabilities
CA$171.1k
CAGR 3-Years
21%
CAGR 5-Years
0%
CAGR 10-Years
-13%
No Stocks Found

Arch Biopartners Inc
Glance View

Market Cap
125.3m CAD
Industry
Life Sciences Tools & Services

Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.

ARCH Intrinsic Value
0.29 CAD
Overvaluation 85%
Intrinsic Value
Price

See Also

What is Arch Biopartners Inc's Total Current Liabilities?
Total Current Liabilities
7.6m CAD

Based on the financial report for Jun 30, 2024, Arch Biopartners Inc's Total Current Liabilities amounts to 7.6m CAD.

What is Arch Biopartners Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
32%

Over the last year, the Total Current Liabilities growth was 77%. The average annual Total Current Liabilities growth rates for Arch Biopartners Inc have been 23% over the past three years , 92% over the past five years , and 32% over the past ten years .

Back to Top